Update on imaging in chronic kidney disease-mineral and bone disorder: promising role of functional imaging

Sharjeel Usmani 1, Najeeb Ahmed 2 3, Gopinath Gnanasegaran 4, Fahad Marafi 5, Tim van den Wyngaert 6


 

Affiliations

01 May 2022

-

doi: 10.1007/s00256-021-03905-6

Abstract

Disorders of mineral metabolism and bone disease are common complications in chronic kidney disease (CKD) patients and are associated with increased morbidity and mortality. Bone biopsies, bone scintigraphy, biochemical markers, and plain films have been used to assess bone disorders and bone turnover. Of these, functional imaging is less invasive than bone/marrow sampling, more specific than serum markers and is therefore ideally placed to assess total skeletal metabolism. 18F-sodium fluoride (NaF) PET/CT is an excellent bone-seeking agent superior to conventional bone scan in CKD patients due to its high bone uptake, rapid single-pass extraction, and minimal binding to serum proteins. Due to these properties, 18F-NaF can better assess the skeletal metabolism on primary diagnosis and following treatment in CKD patients. With the increased accessibility of PET scanners, it is likely that PET scanning with bone-specific tracers such as 18F-NaF will be used more regularly for clinical assessment and quantitation of bone kinetics. This article describes the pattern of scintigraphic/functional appearances secondary to musculoskeletal alterations that might occur in patients with CKD.

Keywords: 18F-NaF PET/CT; Chronic kidney disease; Chronic kidney disease-mineral bone disorder; Renal dialysis.


 

References

 

  1. Kidney disease: improving global outcomes (KDIGO) CKDMBD working group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD). Kidney Int. 2009;Suppl 113: S1-S130.
  2. Jha V, Gaecia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382:260–72. - PubMed
  3. National Institutes of Health. 2016 USRDS Annual Data Report: epidemiology of kidney disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases;2016.
  4. Centers for disease control and prevention. Chronic Kidney Disease Surveillance System—United States. website. http://www.cdc.gov/ckd . Accessed 30th August 2021.
  5. Kazancioğlu R. Risk factors for chronic kidney disease: an update. Kidney Int Suppl. 2011;2013(3):368–71.
  6. Ketteler M, Block GA, Evenepoel P, et al. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD. Kidney Int Suppl. 2017;7(Suppl 1):1–59.
  7. Sidibé A, Moore L, Jean S, et al. Fracture risk in dialysis and kidney transplanted patients: a protocol for systematic review and meta-analysis. Syst Rev. 2017;6(1):37. - PubMed - PMC
  8. Butler AM, Olshan AF, Kshirsagar AV, et al. Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996–2009. Am J Kidney Dis. 2015;65:763. - PubMed - PMC
  9. Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA. 2006;296:2823–31. - PubMed
  10. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2006;69:1945–53. - PubMed
  11. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(suppl 3):S1-201.
  12. Coen G, Ballanti P, Bonucci E, et al. Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH. Nephron. 2002;91:103–11. - PubMed
  13. Davenport MS, Perazella MA, Yee J, et al. Use of intravenous iodinated contrast media in patients with kidney disease: consensus statements from the American College of Radiology and the National Kidney Foundation. Radiology. 2020;294:660–8. - PubMed - PMC
  14. Malluche HH, Monier-Faugere MC. Risk of adynamic bone disease in dialyzed patients. Kidney Int Suppl. 1992;38:S62–7. - PubMed
  15. Vervoloet MG, Brandenburg VM. Circulating markers of bone turnover. J Nephrol. 2017;30:663–70.
  16. Belino C, Meng C, Pereira L, et al. The role of bone biomarkers and new imaging techniques in the management of patients with CKD-MBD. Port J Nephrol Hypert. 2017;31:293–9.
  17. Evenepoel P, Cavalier E, D’Haese PC. Biomarkers predicting bone turnover in the setting of CKD. Curr Osteoporos Rep. 2017;15:178–86. - PubMed
  18. Pelletier S, Dubourg L, Carlier MC, et al. The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol. 2013;8:819–23. - PubMed - PMC
  19. Smith ER. The use of fibroblast growth factor 23 testing in patients with kidney disease. Clin J Am Soc Nephrol. 2014;9:1283–303. - PubMed - PMC
  20. Fliser D, Kollerits B, Neyer U, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007;18:2600–8. - PubMed
  21. Nakatani T, Sarraj B, Ohnishi M, et al. In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) –mediated regulation of systemic phosphate homeostasis. FASEB J. 2009;23:433–41. - PubMed - PMC
  22. Zou D, Wu W, He Y, Ma S, Gao J. The role of Klotho in chronic kidney disease. BMC Nephrol. 2018;19:285–97. - PubMed - PMC
  23. Malluche HH, Monier-Faugere MC. Renal osteodystrophy: what’s in a name? Presentation of a clinically useful new model to interpret bone histologic findings. Clin Nephrol. 2006;65:235–42. - PubMed
  24. Moorthi RN, Moe SM. Recent advances in the noninvasive diagnosis of renal osteodystrophy. Kidney Int. 2013;84:886–94. - PubMed - PMC
  25. Joy MS, Karagiannis PC, Peyerl FW. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm. 2007;13:397–411. - PubMed
  26. Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, et al. The spectrum of bone disease in end-stage renal failure–an evolving disorder. Kidney Int. 1993;43:436–42. - PubMed
  27. Brandenburg V, Floege J. Adynamic bone disease-bone and beyond. NDT Plus. 2008;3:135–47.
  28. Rocha LA, Higa A, Barreto FC, et al. Variant of adynamic bone disease in hemodialysis patients: fact or fiction? Am J Kidney Dis. 2006;48:430–6. - PubMed
  29. Andress DL. Adynamic bone in patients with chronic kidney disease. Kidney Int. 2008;73:1345–54. - PubMed
  30. Sprague SM, Bellorin-Font E, Jorgetti V, Carvalho AB, Malluche HH, Ferreira A, et al. Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis. 2016;67:559–66. - PubMed
  31. Lim CY, Ong KO. Various musculoskeletal manifestations of chronic renal insufficiency. Clin Radiol. 2013;68:e397–411. - PubMed
  32. Goodman WG, Quarles LD. Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics. Kidney Int. 2008;74:276–88. - PubMed
  33. Resnick D, Niwayama G. Parathyroid disorders and renal osteodystrophy. In: Resnick D, Niwayama G, editors. Diagnosis of bone and joint disorders. Philadelphia: W.B. Saunders; 1995. p. 2012–75.
  34. Murphey MD, Sartoris DJ, Quale JL, et al. Musculoskeletal manifestations of chronic renal insufficiency. Radiographics. 1993;13:357–79. - PubMed
  35. Wittenberg A. The rugger jersey spine sign. Radiology. 2004;230:491–2. - PubMed
  36. Mataliotakis G, Lykissas MG, Mavrodontidis AN, et al. Femoral neck fractures secondary to renal osteodystrophy: literature review and treatment algorithm. J Musculoskelet Neuronal Interact. 2009;9:130–7. - PubMed
  37. Al-Gahtany M, Cusimano M, Singer W, Bilbao J, Kovacs K, Marotta T. Brown tumors of the skull base. Case report and review of the literature. J Neurosurg. 2003;98:417–20.
  38. Jevtic V. Imaging of renal osteodystrophy. Eur J Radiol. 2003;46:85–95. - PubMed
  39. Scarpioni R, Ricardi M, Albertazzi V, et al. Dialysis-related amyloidosis: challenges and solutions. Int J Nephrol Renovasc Dis. 2016;9:319–28. - PubMed - PMC
  40. Kiss E, Keusch G, Zanetti M, et al. Dialysis-related amyloidosis revisited. AJR Am J Roentgenol. 2005;185:1460. - PubMed
  41. Danesh F, Ho LT. Dialysis-related amyloidosis: history and clinical manifestations. Semin Dial. 2001;14:80–5. - PubMed
  42. Maruyama H, Gejyo F, Arakawa M. Clinical studies of destructive spondyloarthropathy in long-term hemodialysis patients. Nephron. 1992;61:37–44. - PubMed
  43. Jaffe JA, Liftman C, Glickman JM. Frequency of elevated serum aluminum levels in adult dialysis patients. AM J Kidney Dis. 2005;66:316–9.
  44. Sundaram M, Dessner D, Ballal S. Solitary, spontaneous cervical and large bone fractures in aluminum osteodystrophy. Skeletal Radiol. 1991;20:91–4. - PubMed
  45. Langevitz P, Buskila D, Stewart J, et al. Osteonecrosis in patients receiving dialysis: report of two cases and review of the literature. J Rheumatol. 1990;17:402–6. - PubMed
  46. Jones N, Kjellstrand CM. Spontaneous tendon ruptures in patients on chronic dialysis. Am J Kidney Dis. 1996;28:861–6. - PubMed
  47. Resnick D. Abnormalities of bone and soft tissue following renal transplantation. Semin Roentgenol. 1978; i3:329–340.
  48. Moorthi RN, Moe SM. Recent advances in the non-invasive diagnosis of renal osteodystrophy. Kidney Int. 2013;84:886–94. - PubMed - PMC
  49. Bover J, Bailone L, López-Báez V, Benito S, Ciceri P, Galassi A, et al. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. J Nephrol. 2017. https://doi.org/10.1007/s40620-017-0404-z . - DOI - PubMed
  50. Lobao R, Carvalho AB, Cuppari L, et al. High prevalence of low bone mineral density in pre-dialysis chronic kidney disease patients: bone histomorphometric analysis. Clin Nephrol. 2004;62:432–9. - PubMed
  51. Pimentel A, Bover J, Elder G, et al. The use of imaging techniques in chronic kidney disease-mineral and bone disorders (ckd-mbd)-a systematic review. Diagnostics (Basel). 2021;11:772.
  52. Jamal S, Cheung AM, West S, et al. Bone mineral density by DXA and HR pQCT can discriminate fracture status in men and women with stages 3 to 5 chronic kidney disease. Osteoporos Int. 2012;23:2805–13. - PubMed
  53. Seeman E, Delmas PD. Bone quality–the material and structural basis of bone strength and fragility. N Engl J Med. 2006;354:2250–61. - PubMed
  54. Jamal SA, Gilbert J, Gordon C, et al. Cortical pQCT measures are associated with fractures in dialysis patients. J Bone Miner Res. 2006;21:543–8. - PubMed
  55. Lala D, Cheung AM, Gordon C, et al. Comparison of cortical bone measurements between pQCT and HR-pQCT. J Clin Densitom. 2012;15:275–81. - PubMed
  56. Bacchetta J, Boutroy S, Vilayphiou N, et al. Early impairment of trabecular microarchitecture assessed with HR-pQCT in patients with stage II-IV chronic kidney disease. J Bone Miner Res. 2010;25:849–57. - PubMed
  57. Sharma AK, Masterson R, Holt SG, et al. Emerging role of high resolution imaging in the detection of renal osteodystrophy. Nephrology. 2016;21:801–11. - PubMed
  58. Folkesson J, Goldenstein J, Carballido-Gamio J, et al. Longitudinal evaluation of the effects of alendronate on MRI bone microarchitecture in postmenopausal osteopenic women. Bone. 2011;48:611–21. - PubMed
  59. Frost ML, Blake GM, Park-Holohan SJ, et al. Long-term precision of 18F-fluoride PET skeletal kinetic studies in the assessment of bone metabolism. J Nucl Med. 2008;49:700–7. - PubMed
  60. Hawkins RA, Choi Y, Huang SC, et al. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J NuclMed. 1992;33:633–42.
  61. Frost ML, Cook GJR, Blake GM, et al. A prospective study of risedronate on regional bone metabolism and blood flow at the lumbar spine measured by 18Ffluoride positron emission tomography. J Bone Miner Res. 2003;18:2215–22. - PubMed
  62. Uchida K, Nakajima H, Miyazaki T, et al. Effects of alendronate on bone metabolism in glucocorticoid-induced osteoporosis measured by 18F-fluoride PET: a prospective study. J Nucl Med. 2009;50:1808–14. - PubMed
  63. Installe J, Nzeusseu A, Bol A, et al. 18F-fluoride PET formonitoring therapeutic response in Paget’s disease of bone. J Nucl Med. 2005;46:1650–8. - PubMed
  64. Messa C, Goodman WG, Hoh CK, et al. Bone metabolic activity measured with positron emission tomography and [18F]fluoride ion in renal osteodystrophy: correlation with bone histomorphometry. J Clin Endocrinol Metab. 1993;77:949–55. - PubMed
  65. Aaltonen L, Koivuviita N, Seppänen M, et al. Correlation between 18F-Sodium Fluoride positron emission tomography and bone histomorphometry in dialysis patients. Bone. 2020.
  66. Usmani S, Marafi F, Esmail A, et al. A proof of concept study analyzing the clinical utility of 18F-sodium fluoride (NaF) PET-CT in skeletal staging of oncology patients with end-stage renal disease on dialysis. Nucl Med Commun. 2017;38:1067–75. - PubMed
  67. Aaltonen L, Koivuviita N, Seppänen M, et al. Bone histomorphometry and 18F-sodium fluoride positron emission tomography imaging: comparison between only bone turnover-based and unified TMV-based classification of renal osteodystrophy [published online ahead of print, 2021 Jun 17]. Calcif Tissue Int. 2021; https://doi.org/10.1007/s00223-021-00874-9 .
  68. Cook GJ, Lodge MA, Blake GM, et al. Differences in skeletal kinetics between vertebral and humeral bone measured by 18F-fluoride positron emission tomography in postmenopausal women. J Bone Miner Res. 2000;15:763–9. - PubMed
  69. Torres A, Lorenzo V, Hernandez D, et al. Bone disease in predialysis, hemodialysis, and CAPD patients: Evidence of a better bone response to PTH. Kidney Int. 1995;47:1434–42. - PubMed
  70. Stacul F, van der Molen, Aart J, Reimer P, Webb JA, et al. Contrast induced nephropathy: updated ESUR contrast media safety committee guidelines. Eur Radiol. 2011;21: 2527–2541.
  71. Polena S, Yang S, Alam R, Gricius J, Gupta JR, et al. Nephropathy in critically Ill patients without preexisting renal disease. Proc West Pharmacol Soc. 2005;48:134–5. - PubMed
  72. Katzberg RW, Newhouse JH. Intravenous contrast medium-induced nephrotoxicity: is the medical risk really as great as we have come to believe? Radiology. 2010;1:21–8.
  73. Khawaja AZ, Cassidy DB, Al Shakarchi J, et al. Revisiting the risks of MRI with gadolinium based contrast agents-review of literature and guidelines. Insights Imaging. 2015;6:553–8. - PubMed - PMC
  74. European Medicines Agency (2010) Assessment report for gadolinium-containing contrast agents. In: Proced. No. EMEA/H/A-31/1097.
  75. Ryan PJ, Fogelman I. Bone scintigraphy in metabolic bone disease. Semin Nucl Med. 1997;27:291–305. - PubMed
  76. Abdelrazek S, Szumowski P, Rogowski F, et al. Bone scan in metabolic bone diseases. Review. Nucl Med Rev Cent East Eur. 2012;15:124–131.
  77. Fogelman I, McKillop JH, Greig WR, et al. Pseudofractures of the ribs detected by bone scanning. J Nucl Med. 1977;18:1236–7. - PubMed
  78. de Graaf P, Schicht IM, Pauwels EK, et al. Bone scintigraphic in uremic pulmonary calcification. J Nucl Med. 1984;20:201–6.
  79. Czernin J, Satyamurthy N, Schiepers C. Molecular mechanisms of bone 18F-NaF deposition. J Nucl Med. 2010;51:1826–9. - PubMed
  80. Vaz S, Usmani S, Gnanasegaran G, et al. Molecular imaging of bone metastases using bone targeted tracers. Q J Nucl Med Mol Imaging. 2019;63:112–28. - PubMed
  81. Even-Sapir E, Metser U, Mishani E, et al. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47:287–97. - PubMed
  82. Segall G, Delbeke D, Stabin MG, et al. SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0. J Nucl Med. 2010;51:1813–20. - PubMed
  83. Kuhlman JE, Ren H, Hutchins GM, Fishman EK. Fulminant pulmonary calcification complicating renal transplantation: CT demonstration. Radiology. 1989;173:459–60. - PubMed
  84. Fathi I, Sakr M. Review of tumoral calcinosis: a rare clinico-pathological entity. World J Clin Cases. 2014;2:409–14. - PubMed - PMC
  85. Mizobuchi M, Towler D, Slatopolsky E, et al. Vasuclar calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol. 2009;20:1453–64. - PubMed
  86. Stompór T. Coronary artery calcification in chronic kidney disease: An update. World J Cardiol. 2014;6:115–29. - PubMed - PMC
  87. Dweck MR, Chow MW, Joshi NV, et al. Coronary arterial 18F-sodium fluoride uptake: a novel marker of plaque biology. J Am Coll Cardiol. 2012;59:1539–48. - PubMed
  88. Joshi NV, Vesey AT, Williams MC, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet. 2014;383:705–13. - PubMed
  89. Derlin T, Richter U, Bannas P, et al. Feasibility of 18F-sodium fluoride PET/CT for imaging of atherosclerotic plaque. J Nucl Med. 2010;51:862–5. - PubMed
  90. Derlin T, Wisotzki C, Richter U, et al. In vivo imaging of mineral deposition in carotid plaque using 18F-sodium fluoride PET/CT: correlation with atherogenic risk factors. J Nucl Med. 2011;52:362–8. - PubMed
  91. Li L, Li X, Jia Y, et al. Sodium-fluoride PET-CT for the non-invasive evaluation of coronary plaques in symptomatic patients with coronary artery disease: a cross-correlation study with intravascular ultrasound. Eur J Nucl Med Mol Imaging. 2018;45:2181–9. - PubMed - PMC
  92. Silva Mendes BI, Oliveira-Santos M, Vidigal Ferreira MJ. Sodium fluoride in cardiovascular disorders: a systematic review. J Nucl Cardiol. 2019. Aug 6. [Epub ahead of print].
  93. Yoder JS, Kogan F, Gold GE. PET-MRI for the study of metabolic bone disease. Curr Osteoporos Rep. 2018;16:665–73. - PubMed - PMC

Page Navigation